热点栏目 自选股 数据中心 行情中心 资金流向 模拟交易 客户端 热点栏目 自选股 数据中心 行情中心 资金流向 模拟交易 客户端 科济药业-B（02171）午前股价上涨4.22%，现报16.31港元，成交额730.22万港元。 科济药业-B（02171）午前股价上涨4.22%，现报16.31港元，成交额730.22万港元。 近日，据科技药业官微消息，公司宣布，与Dispatch Bio（一家利用其首创Flare平台开发通用型实体瘤 治疗方法的生物技术公司）达成临床合作，计划于2026年在中国启动一项I期临床试验。该试验将评估 联合疗法DISP-11在实体瘤患者的中的应用。 据介绍，该联合疗法由Dispatch公司首创Flare平台开发的在研疗法（包括其新型肿瘤特异性病毒DV- 10）与科济药业的靶向BCMA自体CAR-T细胞产品赛恺泽®（泽沃基奥仑赛注射液）联用组成。赛恺泽 ®已获得中国国家药品监督管理局（NMPA）批准用于治疗多发性骨髓瘤。 责任编辑：卢昱君 近日，据科技药业官微消息，公司宣布，与Dispatch Bio（一家利用其首创Flare平台开发通用型实体瘤 治疗方法的生物技术公司）达成临床合作， ...

科济药业-B(02171)涨近4%，截至发稿，涨3.96%，报16.27港元，成交额494.17万港元。 据介绍，该联合疗法由Dispatch公司首创Flare平台开发的在研疗法(包括其新型肿瘤特异性病毒DV-10)与 科济药业的靶向BCMA自体CAR-T细胞产品赛恺泽(泽沃基奥仑赛注射液)联用组成。赛恺泽已获得中国 国家药品监督管理局(NMPA)批准用于治疗多发性骨髓瘤。 消息面上，近日，据科技药业官微消息，公司宣布，与Dispatch Bio(一家利用其首创Flare平台开发通用 型实体瘤治疗方法的生物技术公司)达成临床合作，计划于2026年在中国启动一项I期临床试验。该试验 将评估联合疗法DISP-11在实体瘤患者的中的应用。 ...

智通财经APP获悉，科济药业-B(02171)涨近4%，截至发稿，涨3.96%，报16.27港元，成交额494.17万港 元。 消息面上，近日，据科技药业官微消息，公司宣布，与Dispatch Bio(一家利用其首创Flare平台开发通用 型实体瘤治疗方法的生物技术公司)达成临床合作，计划于2026年在中国启动一项I期临床试验。该试验 将评估联合疗法DISP-11在实体瘤患者的中的应用。 据介绍，该联合疗法由Dispatch公司首创Flare平台开发的在研疗法(包括其新型肿瘤特异性病毒DV-10)与 科济药业的靶向BCMA自体CAR-T细胞产品赛恺泽(泽沃基奥仑赛注射液)联用组成。赛恺泽®已获得中 国国家药品监督管理局(NMPA)批准用于治疗多发性骨髓瘤。 ...

Core Insights - The article discusses the rapid growth and development of immunotherapy for cancer treatment, particularly focusing on immune cell therapies such as CAR-T, CAR-NK, TCR-T, and TIL therapies, which have become a significant fourth modality in cancer treatment alongside surgery, radiation, and drug therapy [1][4]. Industry Overview - Immunotherapy involves collecting young, healthy immune cells, expanding them in vitro, enhancing their targeting capabilities, and reinfusing them into patients to combat pathogens, cancer cells, and mutated cells [1][4]. - The global market for tumor immunotherapy products is projected to grow at a compound annual growth rate (CAGR) of 149.1% from 2017 to 2024, reaching a market size of $7.1 billion by 2025 [1][6]. - In China, the market for tumor immunotherapy products is expected to reach 2.1 billion yuan by 2025, driven by the approval of various immune cell therapy products [1][8]. Development Background - China has the highest incidence and mortality rates of cancer globally, with 4.8247 million new cases and 2.5742 million deaths reported in 2022, accounting for 24.1% and 26.5% of global totals, respectively [4]. - The increasing disposable income of Chinese residents has improved their ability to pay for medical care, with healthcare spending projected to reach 2,547 yuan per capita in 2024, growing by 3.6% [4][5]. Current Market Status - As of the end of 2024, there are 1,040 immunotherapy products in clinical trials, with the U.S. and China leading in the number of trials [10]. - CAR-T therapy is the most commercially mature and widely tested method, with 15 drugs approved globally by December 2025, 8 of which are approved in China [12]. Future Trends - The clinical transformation of immunotherapy is expected to accelerate, with market penetration likely to expand, potentially exceeding 10 billion yuan by 2027 [13]. - Advances in gene editing and AI-assisted target selection are anticipated to enhance treatment precision, while universal and multi-target cell products are expected to become mainstream in research [13][14].

机构：天风证券 研究员：杨松/曹文清 临床数据显示，该药在多种实体瘤尤其在胃癌后线治疗领域表现优异，II期临床达到主要终点。在 ASCO 2025 公布的研究中，相较于接受TPC 治疗的患者，CT041 在入组的所有至少二线治疗失败的 CLDN18.2 阳性G/GEJC患者中显著改善PFS（mPFS 3.25 vs 1.77 个月，HR = 0.366），同时展现了OS 获 益趋势（7.92 vs 5.49 个月,HR 0.693，单侧p=0.0416）。在实际接受输注的患者中，CT041 和TPC 的 mPFS 分别为4.37 个月 vs 1.84 个月，HR 为0.304，mOS 为8.61 个月 vs 5.49 个月，HR 为0.601。 通用型CAR-T 平台THANK-u Plus加速推进，CT0596 疗效信号积极在自体CAR-T 商业化取得里程碑式 成果后，公司同步布局通用型CAR-T 技术平台 THANK-u Plus，致力于实现细胞治疗的标准化和批量化 生产。该平台通过优化NKG2A 调控机制，使CAR-T 在不同免疫环境下仍具持续扩增能力，显著改善了 异体细胞治疗中的免疫排斥问题。基于此平 ...

该试验将评估联合疗法DISP-11在实体瘤患者的中的应用。该联合疗法由Dispatch公司首创Flare平台开 发的在研疗法（包括其新型肿瘤特异性病毒DV-10）与科济药业的靶向BCMA自体CAR-T细胞产品赛恺 泽 （泽沃基奥仑赛注射液，产品编号：CT053）联用组成。赛恺泽 已获得中国国家药品监督管理局 （NMPA）批准用于治疗多发性骨髓瘤。 近日，科济药业公众号发布公告称，公司与Dispatch Bio宣布达成临床合作，计划于2026年在中国启动 一项I期临床试验。 ...

Core Insights - The new medical insurance directory has entered a substantial implementation phase, with several innovative drugs, including Tislelizumab and Fuzhengzhu, being prescribed under insurance in various hospitals, indicating a reduction in access barriers for patients [1] - The adjustment includes 114 new drugs and introduces a commercial health insurance directory for innovative drugs, marking a significant shift towards a multi-tiered insurance system [1][5] - The rapid inclusion of innovative drugs in the insurance directory reflects increased support for "true innovation" with high clinical value [5] Group 1: New Drug Inclusion - The new medical insurance directory has added 124 unique products, including Tislelizumab, the first targeted drug for thyroid eye disease, and Fuzhengzhu, a biological agent for psoriasis [5] - Heng Rui Medicine is a major beneficiary, with 20 products and indications adjusted, including 10 new drugs entering the directory for the first time [5][6] - Other biotech companies like BeiGene and Innovent Biologics have also benefited, with multiple products included in the new directory, enhancing their commercialization prospects [7] Group 2: Commercial Health Insurance Directory - The introduction of the commercial health insurance directory provides a secondary market for high-value innovative drugs, with price reductions ranging from 15% to 50%, which is less severe than the basic insurance cuts [9] - The directory aims to improve accessibility for high-priced drugs while ensuring adequate returns for pharmaceutical companies [9] - Notable CAR-T therapies have been included in the commercial directory, overcoming previous barriers to entry, with prices for these therapies exceeding 1 million yuan [8][10] Group 3: Market Dynamics and Drug Exits - The adjustment process has also seen the removal of 29 drugs from the insurance directory, including Benarutide, which faced competition from more effective alternatives [12][14] - The dynamic adjustment mechanism emphasizes the need for drugs to demonstrate clinical value, reinforcing a "can enter, can exit" policy [14] - Companies are encouraged to shift from "me-too" products to genuine innovations, focusing on high-value areas such as oncology and rare diseases [10][14]

致：香港交易及結算所有限公司 公司名稱: 科濟藥業控股有限公司 呈交日期: 2026年1月7日 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年12月31日 狀態: 新提交 FF301 第 1 頁 共 10 頁 v 1.1.1 FF301 II. 已發行股份及/或庫存股份變動 | 1. 股份分類 | 普通股 | | 股份類別 | 不適用 | 於香港聯交所上市 (註1) | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02171 | 說明 | | | | | | | | | 已發行股份（不包括庫存股份）數目 | | 庫存股份數目 | | 已發行股份總數 | | | 上月底結存 | | | 574,242,655 | | 3,730,500 | | 577,973,155 | | 增加 / 減少 (-) | | | -3,943,656 | | 4,087,500 | | | | 本月底結存 | | | 570,298,999 | | 7,818,000 | | ...

（文章来源：每日经济新闻） 每经AI快讯，科济药业-B(02171.HK)涨近6%，截至发稿涨5.94%，报16.23港元，成交额1880.74万港 元。 ...

据介绍，本项目所属的"实体肿瘤的免疫细胞治疗新型药物研发"方向，将针对实体瘤治疗中存在的临床 与科学瓶颈，系统推进新一代免疫细胞治疗的源头创新与技术攻关。项目将聚焦实体瘤免疫细胞治疗的 前沿领域，着力开发具有突破性的治疗技术与创新产品，推动相关药物的临床转化与工程化制备体系建 设。 智通财经APP获悉，科济药业-B(02171)涨近6%，截至发稿，涨5.94%，报16.23港元，成交额1880.74万 港元。 消息面上，12月30日，据科济药业官微消息，公司宣布，由旗下上海科济制药有限公司牵头申报的"实 体肿瘤的免疫细胞治疗关键技术和 创新药 研发"项目，正式获批列入创新药物研发国家科技重大专项 2025年度项目立项清单。据悉，国家科技重大专项是我国在战略前沿领域布局的最高层次科研攻关计 划，旨在实现关键核心技术的自主突破与产业转化。 ...